Ophthalmology

The professor from University of Pittsburgh School of Medicine discussed the combination of an optogenetics device and gene therapy in treatment of RP.

Review top news and interview highlights from the week ending November 19, 2021.

The chief executive officer of California Retina Consultants discussed the positive results of RGX-314 gene therapy in wet AMD.

The Doheny Image Reading and Research Lab is leading a sub study to analyze OCT images with their proprietary 3D-OCTOR software.

Dan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the company’s ultimate goal of reversing aging.

The professor of medicine at Duke University School of Medicine previously served as commissioner in 2016.

Investigators are planning a first-in-man clinical trial for photoreceptor precursor transplant in Singapore.

Review top news and interview highlights from the week ending November 5, 2021.

4D Molecular Therapeutics announced positive data from trials assessing 2 of their gene therapies.

Partners in the Bespoke Gene Therapy Consortium include the NIH, FDA, private companies such as Pfizer and Biogen, and non-profits.

André Choulika, PhD, chief executive officer and cofounder, Cellectis, discussed the company’s expansion into gene therapies.

Researchers have developed a corneal epithelial stem cell-derived eye drop therapy for dry eye disease.

Review top news and interview highlights from the week ending October 29, 2021.

John Pollack, MD, discusses gene therapy advancements for retinal diseases.

Review top news and interview highlights from the week ending October 22, 2021.

The director of the Powell Gene Therapy Center at the University of Florida discussed improving access to gene therapies for patients with rare diseases worldwide.

4D Molecular Therapeuitcs plans to initiate a phase 1/2 trial of 4D-150 before the end of the year.

Results from a phase 1/2 study from Nanoscope Therapeutics were presented at the 2021 ASRS meeting.

Review top news and interview highlights from the week ending October 15, 2021.

The cell therapy yielded improvements in visual acuity and central corneal thickness.

New human gene editing therapies, drug discoveries, targets, and CRISPR technology holds the potential to usher in a new age in medicine.

REGENXBIO previously announced positive data in patients with wet AMD who were treated with the same gene therapy.

Review top news and interview highlights from the week ending October 8, 2021.

The director of the Powell Gene Therapy Center at the University of Florida discussed adverse events in gene therapies.

Paul Wotton, PhD, chief executive officer, Obsidian Therapeutics, discussed the company’s pipeline and technologies.